Coronary Intervention Articles & Analysis
37 news found
Food and Drug Administration (FDA) for XC001 as adjunctive therapy to coronary artery bypass grafting (CABG) in 2H21. The company also plans other clinical studies in additional cardiovascular indications, including heart failure caused by ischemic heart disease and as adjunctive therapy to percutaneous coronary intervention. ...
PMD announced it will present its first-in-human results for the ModulHeartTM in the following session during the American Heart Association (AHA) meeting held November 5–7, 2022 at the McCormick Place Convention Center in Chicago, IL: Four patients had ModulHeartTM deployed to provide circulatory support while undergoing high-risk percutaneous coronary ...
EMPOWER CAD is the First Prospective, Female-Only Study of Coronary Interventions Study Seeks to Confirm Benefits of Shockwave’s Coronary IVL in Females Who Historically Have Suffered Less Favorable Clinical Outcomes than Male Patients with Traditional Therapies Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of ...
Four patients had ModulHeartTM deployed to provide circulatory support while undergoing high-risk percutaneous coronary intervention procedures. All patients experienced improvements in cardiac and kidney function. ...
This is the first step towards obtaining approval from China’s National Medical Products Administration (NMPA) for the commercialization of R-One™, its robotic solution for PCI (Percutaneous Coronary Intervention) in the Chinese market, where this is the first clinical study conducted on this scale in the field of vascular robotics. ...
ByRobocath
Four patients had ModulHeart deployed to provide circulatory support while undergoing high-risk percutaneous coronary intervention (PCI) procedures. All patients experienced improvements in cardiac and kidney function. ...
About the EXACT Study The Epicardial Delivery of XC001 Gene Therapy for Refractory Angina Coronary Treatment (EXACT) clinical trial is a Phase 1/2 multicenter, open-label, single-arm trial. ...
About the EXACT Study The Epicardial Delivery of XC001 Gene Therapy for Refractory Angina Coronary Treatment (EXACT) clinical trial is a Phase 1/2 multicenter, open-label, single-arm trial. ...
Miracor Medical SA (Miracor Medical) today announced the first patient enrolled in the PICSO-AMI-V study to evaluate the benefits of PiCSO® (Pressure-controlled intermittent Coronary Sinus Occlusion) therapy as an adjunct to conventional primary percutaneous coronary intervention (PCI) for patients presenting with inferior ST-Elevation ...
The BIOADAPTOR RCT is evaluating the DynamX™ Coronary Bioadaptor System, the first drug-eluting coronary artery implant that adapts to vessel physiology, allowing for the restoration of normal vessel functions essential to cardiovascular performance. ...
The system also allowed for excellent commissural alignment; a significant patient benefit if future coronary intervention were required. A 20% increase from baseline in 6 min walk test (a measure of patient exercise tolerance). ...
Infraredx, a Nipro Company, a pioneer in intravascular imaging for mapping coronary artery disease, announced today the enrollment of the first patient in its EXPANSE PTCA study (NCT04985773) at the Cardiology Associates of North Mississippi in Tupelo, Mississippi. The study will be conducted in the United States with the objective to evaluate safety and effectiveness of the ...
Saranas, Inc., has announced initiation and first patient enrollment in SAFE-MCS, a multi-center, single arm, open-label clinical trial evaluating the safety of complex high-risk percutaneous coronary intervention (PCI) using mechanical circulatory support (MCS) and surveillance with the Early Bird Bleed Monitoring System. ...
Taylor, Chief of the Division of Cardiac Surgery and Director of Coronary Revascularization and site Principal Investigator at the University of Maryland Medical Center. ...
About Chronic Refractory Angina Chronic angina pectoris occurs when the heart muscle does not receive as much oxygen as it needs for the amount of work it is performing, and this often results in chest pain. This is usually due to coronary artery disease. Patients with chronic angina who are symptomatic despite optimal medical therapy and are no longer eligible for mechanical ...
Miracor Medical Miracor Medical developed the Pressure-controlled intermittent Coronary Sinus Occlusion (PiCSO) therapy to be used during percutaneous coronary intervention in patients with acute myocardial infarction. ...
Robocath, a company that designs, develops and commercializes cardiovascular robotic platforms for the treatment of vascular diseases, today announces the successful completion of first five robotic coronary angioplasties in Belgium. The Percutaneous Coronary Interventions (PCI) were performed on April 8 and 13 by Prof. Stefan Verheye, a ...
ByRobocath
Despite a significant reduction in ISR when using a drug-eluting stent (DES), a recent study has shown that ISR represents approximately 10% of all percutaneous coronary interventions in the U.S.1 With a shared interest in the study, BIS and Infraredx will pool clinical expertise and financial resources to execute the U.S. study. ...
“Corindus has made significant progress toward our goal of expanding access to care through remote robotic interventions,” said Wayne Markowitz, Executive Vice President and Head of Corindus. ...
“Corindus has made significant progress toward our goal of expanding access to care through remote robotic interventions,” said Wayne Markowitz, Executive Vice President and Head of Corindus. ...